Included study information
Author | Year | World Bank category | Country | Funder | Sex | Total participants (n=) | Risk of bias (RCT or QE) | |
Intervention | Study | |||||||
Abramsky | 2014 | LIC | Uganda | Irish Aid; Sigrid Rausing Trust; 3ie; AusAID; Stephen Lewis Foundation; American Jewish World Service; HIVOS; NoVo Foundation | M+F | M+F | Baseline: 1583; Endline: 2532 | Some concerns (RCT) |
Abramsky | 2016 | LIC | Uganda | See above | M+F | M+F | Baseline: 1583; Endline: 2532 | Some concerns (RCT) |
Achyut | 2011 | MIC | India | John D. and Catherine T. MacArthur Foundation; Nike Foundation | M+F | M+F | Baseline: 2896; Follow-up: 203; Endline: 754 | Serious (QE) |
Ara | 2010 | LIC | Bangladesh | BRAC & international partners | M+F | M+F | Baseline: 1534; Endline: 797 | Moderate (QE) |
Ashburn | 2017 | LIC | Uganda | USAID; Oak Foundation | M (small amount of female partner involvement) | M | Baseline: 435; Endline: 400 | Serious (QE) |
Avery-Leaf | 1997 | HIC | USA | NIMH | M+F | M+F | Baseline: 193; Endline: 193 | Moderate (QE) |
Baiocchi | 2017 | MIC | Kenya | Ujamaa-Africa | M+F | F | Baseline: 5686; Endline: 6106 | High (RCT) |
Bartel | 2010 | MIC | India | Ford Foundation | M+F | F | Baseline: 663; Endline: 668 | Serious (QE) |
CAREInternational | 2012 | MIC, HIC | Bosnia and Herzegovina, Serbia, Croatia | CARE International North West Balkans | M | M | >100 | Serious (QE) |
Chamroonsawasdi | 2010 | MIC | Thailand | WHO | M+F | M+F | Baseline: 530; Endline: 530 | Serious (QE) |
Chege | 2004 | LIC, MIC | Ethiopia, Kenya | USAID | M+F | M+F | Baseline: 2259; Endline: 2240 | Serious (QE) |
Cowan | 2010 | MIC | Zimbabwe | NIMH; DfID Zimbabwe | M+F | M+F | Baseline: 6791; Endline: 4684 | High (RCT) |
Daniel | 2008 | MIC | India | David and Lucile Packard Foundation | M+F | F | Baseline: 1995; Endline: 2080 | Moderate (QE) |
Das | 2012 | MIC | India | NIKE Foundation | M | M | 610 | Serious (QE) |
Davis | 2000 | HIC | USA | US DOJ | M | M+F | Baseline: 376; T2: 150*; Endline: 83* | High (RCT) |
Davis | 2002 | HIC | USA | Unspecified | M | M | Baseline: 89; T2: 90; Endline: 89 | High (RCT) |
Diop | 2004 | MIC | Senegal | USAID; Population Council | M+F | M+F | Baseline: 2623; Endline: 2397 | Serious (QE) |
El-Bassel | 2005 | HIC | USA | NIMH | M+F | M+F | Baseline: 298; Endline: 166 | High (RCT) |
Erulkar | 2011 | LIC | Ethiopia | USAID/PEPFAR | M | M | 545 | Serious (QE) |
Exner | 2009 | MIC | Nigeria | NICHD; NIMH; HIV Center for Clinical and Behavioral Studies | M | M | Baseline: 281; Endline: 185 | Moderate (QE) |
Fay | 2006 | HIC | USA | Unspecified | M+F | M+F | Baseline: 154; Endline: 154 | High (RCT) |
Feder | 2000 | HIC | USA | US DOJ | M | M+F | Baseline: 321; Endline: 203 | High (RCT) |
Feder | 2002 | HIC | USA | US NIJ | M | M+F | Baseline: 520; Endline: 325 | High (RCT) |
Feder | 2004 | HIC | USA | US DOJ | M | M+F | Baseline: 520; T2: 325; Endline: 87 | High (RCT) |
Foshee | 1998 | HIC | USA | CDC | M+F | M+F | Baseline: 1886; Endline: 1700 | High (RCT) |
Foshee | 2000 | HIC | USA | CDC | M+F | M+F | Baseline: 1886; T2: 1700; Endline: 1603 | High (RCT) |
Foshee | 2004 | HIC | USA | CDC | M+F | M+F | Baseline: 1886; T2: 1700; T3: 1603; Endline: 460 | High (RCT) |
Foshee | 2005 | HIC | USA | CDC | M+F | M+F | 1566 | High (RCT) |
Foubert | 1997 | HIC | USA | Unspecified | M | M | Baseline: 105; Endline: 77 | Serious (QE) |
Fuertes | 2012 | HIC | Spain | Ministry of Science, Technology, Knowledge and Innovation, Chile | M+F | M+F | Baseline: 169; T2: 169; Endline: 169 | Moderate (QE) |
Gidycz | 2011 | HIC | USA | CDC | M | M | Baseline: 635; T2: 529; Endline: 494 | Some concerns (RCT) |
Gordon | 2003 | HIC | USA | Unspecified | M | M | 248 | Serious (QE) |
Gupta | 2013 | MIC | Côte d’Ivoire | World Bank’s SPF; Center for Interdisciplinary Research on AIDS; NIMH | M+F | M+F | Baseline: 981; Endline: 934 | Some concerns (RCT) |
Harrell | 1991 | HIC | USA | US State Justice Institute | M | M | Baseline: 237; Endline: 193 | Serious (QE) |
Hillenbrand-Gunn | 2010 | HIC | USA | Missouri Department of Health and Senior Service; CDC; NCIPC | M+F | M+F | 212 | Serious (QE) |
Hossain | 2014 | MIC | Côte d’Ivoire | Novo Foundation; Sigrid Rausing Trust; UK ESRC | M | M+F | Baseline: 578; Endline: 548 | High (RCT) |
Instituto Promundo | 2012 | MIC | Brazil, India, Chile | Instituto Promundo; UNTF | India: M+F; Brazil and Chile: M | Not reported | Brazil Pretest: 210; Post-test: 180 Chile Pretest: 510; Post-test: 303 India Pretest: 370; Midline: 267; Post-test: 258 | Serious (QE) |
James | 2006 | MIC | South Africa | Horizons Project (USAID) | M+F | M+F | Baseline: 1141; T2: 844; Endline: 768 | High (RCT) |
Jewkes | 2008 | MIC | South Africa | NIMH | M+F | M+F | Baseline: 2776; T2: 2144; Endline: 2069 | High (RCT) |
Kalichman | 2009 | MIC | South Africa | NIMH | M | M | Baseline: 475; T2: 452; T3: 455; Endline: 432 | Moderate (QE) |
Keller | 2017 | MIC | Kenya | Ujamaa-Africa; No Means No Worldwide | M | M | Baseline: 1543; Endline: 1325 | Serious (QE) |
Kyegombe | 2014 | LIC | Uganda | Irish Aid; Sigrid Rausing Trust; 3ie; UKAID; Stephen Lewis Foundation; HIVos; NoVo Foundation | M+F | M+F | Baseline: 1583; Endline: 2532 | High (RCT) |
Kyegombe | 2015 | LIC | Uganda | See above | M+F | M+F | Baseline: 1583; Endline: 2530 | High (RCT) |
Labriola | 2005 | HIC | USA | US NIJ | M | M | Baseline: 211; Endline: 209 | High (RCT) |
Lin | 2009 | HIC | Taiwan | Department of Health (China) | M | M | Baseline: 340; Endline: 301 | Serious (QE) |
Lundgren | 2013 | LIC | Nepal | USAID | M+F | M+F | Baseline: 603; Endline: 603 | Moderate (QE) |
Macgowan | 1997 | HIC | USA | National Council of Jewish Women | M+F | M+F | Baseline: 740; Endline: 440 | Serious (QE) |
Maxwell | 2004 | HIC | USA | NIJ | M | M | 367 | High (RCT) |
Miller | 2012 | HIC | USA | CDC | M | M | Baseline: 2006; Endline: 1798 | Some concerns (RCT) |
Miller | 2014 | MIC | India | Nike Foundation; US NIH; US HRSA | M | M | Baseline: 663; Endline: 309 | Moderate (QE) |
Pulerwitz | 2006 | MIC | Brazil | Horizons Program (USAID); REPSSI | M | M | Baseline: 780; T2: 622; Endline: 407 | Serious (QE) |
Pulerwitz | 2010 | LIC | Ethiopia | PEPFAR | M | M | Baseline: 729; Endline: 645 | Moderate (QE) |
Pulerwitz | 2015 | LIC | Ethiopia | PEPFAR | M | M | Baseline: 729; Endline: 645 | Moderate (QE) |
Rhodes | 2011 | HIC | USA | NIMH | M | M | Baseline: 142; Endline: 139 | Some concerns (RCT) |
Salazar | 2006 | HIC | USA | Georgia State University | M | M | Baseline: 47; Endline: 36 | High (RCT) |
Salazar | 2014 | HIC | USA | NCIPC; CDC | M | M | Baseline: 743; T2: 451; Endline: 215 | Some concerns (RCT) |
Saunders | 1996 | HIC | USA | CDC; University of Michigan | M | M+F | Baseline: 417; Follow-up: 243 | High (RCT) |
Schuler | 2012 | LIC | Tanzania | C-Change Project & international partners (USAID) | M+F | M+F | Baseline: 764; Endline: 369 | High (RCT) |
Schuler | 2012 | MIC | Guatemala | C-Change Project & international partners (USAID) | M+F | M+F | Baseline: 1122; Endline: 603 | High (RCT) |
Schwarz | 2004 | HIC | USA | Unspecified | M+F | M+F | Baseline: 65; Endline: 58 | Moderate (QE) |
Shattuck | 2011 | LIC | Malawi | Family Health International; USAID | M | M | Baseline: 397; Endline: 289 | Some concerns (RCT) |
Taylor | 2012 | MIC | South Africa | SANPAD | M+F | M+F | Baseline: 816; Endline: 679 | High (RCT) |
Taylor | 2001 | HIC | USA | US NIJ | M | M | Baseline: 376; T2: 171, Endline: 186 | High (RCT) |
Taylor | 2009 | HIC | USA | US NIJ | M | M | 629 | High (RCT) |
Verma | 2008 | MIC | India | PEPFAR | M+F | M | Baseline: 1915; Endline: 1138 | Moderate (QE) |
Wagman | 2015 | LIC | Uganda | Bill & Melinda Gates Foundation; US NIH; WHO; PEPFAR; Fogarty International Center | M+F | M+F | Baseline: 11 448; T2: 7842; Endline: 6526 | High (RCT) |
Weisz | 2001 | HIC | USA | Michigan Community Health Department | M+F | M+F | Baseline: 66; T2 & endline: varied by measure: Knowledge=26 Attitudes=29 Perpetration=23 Victimisation=20 | Moderate (QE) |
Wolfe | 2003 | HIC | Canada | Ontario Mental Health Foundation; NHRDP (Health Canada); SSHRC (Canada) | M+F | M+F | Baseline: 191; Endline: 158 | Moderate (QE) |
*Values imputed from percentages reported by study authors.
F, female; HIC, high-income country; LIC, low-income country; M, male; MIC, middle-income country; QE, quasi-experimental study; RCT, randomised controlled trial.